PT  - JOURNAL ARTICLE
AU  - Mahesh S Dhar
AU  - Robin Marwal
AU  - VS Radhakrishnan
AU  - Kalaiarasan Ponnusamy
AU  - Bani Jolly
AU  - Rahul C. Bhoyar
AU  - Viren Sardana
AU  - Salwa Naushin
AU  - Mercy Rophina
AU  - Thomas A Mellan
AU  - Swapnil Mishra
AU  - Charles Whittaker
AU  - Saman Fatihi
AU  - Meena Datta
AU  - Priyanka Singh
AU  - Uma Sharma
AU  - Rajat Ujjainiya
AU  - Nitin Batheja
AU  - Mohit Kumar Divakar
AU  - Manoj K Singh
AU  - Mohamed Imran
AU  - Vigneshwar Senthivel
AU  - Ranjeet Maurya
AU  - Neha Jha
AU  - Priyanka Mehta
AU  - A Vivekanand
AU  - Pooja Sharma
AU  - VR Arvinden
AU  - Urmila Chaudhary
AU  - Namita Soni
AU  - Lipi Thukral
AU  - Seth Flaxman
AU  - Samir Bhatt
AU  - Rajesh Pandey
AU  - Debasis Dash
AU  - Mohammed Faruq
AU  - Hemlata Lall
AU  - Hema Gogia
AU  - Preeti Madan
AU  - Sanket Kulkarni
AU  - Himanshu Chauhan
AU  - Shantanu Sengupta
AU  - Sandhya Kabra
AU  - The Indian SARS-CoV-2 Genomics Consortium (INSACOG)
AU  - Ravindra K. Gupta
AU  - Sujeet K Singh
AU  - Anurag Agrawal
AU  - Partha Rakshit
TI  - Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
AID  - 10.1101/2021.06.02.21258076
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.02.21258076
4099  - http://medrxiv.org/content/early/2021/08/20/2021.06.02.21258076.short
4100  - http://medrxiv.org/content/early/2021/08/20/2021.06.02.21258076.full
AB  - Delhi, the national capital of India, has experienced multiple SARS-CoV-2 outbreaks in 2020 and reached a population seropositivity of over 50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and partial reduction of immunity elicited by prior infection (median estimates; ×1.5-fold, 20% reduction). Seropositivity of an employee and family cohort increased from 42% to 86% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.One-Sentence Summary Delhi experienced an overwhelming surge of COVID-19 cases and fatalities peaking in May 2021 as the highly transmissible and immune evasive Delta variant replaced the Alpha variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/